Natera reported outstanding Q1 2023 financial results, with revenues soaring to $241.8 million, marking a 24.5% increase from the same period in 2022. The company's product revenues witnessed a ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...
SAN CARLOS, Calif., Jan. 29, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will feature its recently expanded ...
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) and Natera, Inc. today announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq® 2500 ...
SALT LAKE CITY & SAN CARLOS, Calif.--(BUSINESS WIRE)--ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory, and Natera, a leading innovator in reproductive and ...
Since 2020, Desmarais LLP partner Kerri-Ann Limbeek has represented prenatal testing client Ravgen in eight patent cases in district court and at the Patent Trial and Appeal Board. This week, in her ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical ...
When Mara Varona was pregnant she decided to take a common prenatal blood test to screen for genetic conditions. It was part of a proactive approach she and her husband took to pregnancy. "We're just ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback